Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Ligand Pharmaceuticals (LGND)

Ligand Amends Credit Agreement, Extends Maturity to September 12, 2028

Neutral Impact 3 of 5 financing Written later

Ligand Pharmaceuticals signed a Third Amendment to its credit agreement with Citibank, N.A. as administrative agent, extending the loan maturity date to September 12, 2028. The amendment also sets a minimum consolidated EBITDA covenant of $55 million for the trailing four-quarter period ending September 30, 2025 and each period after that.

Key points

  • Third Amendment to Credit Agreement dated September 12, 2025, with Citibank, N.A. as Administrative Agent
  • Maturity date extended to September 12, 2028
  • Minimum consolidated EBITDA covenant of $55 million for trailing four-quarter periods starting with the period ending September 30, 2025
  • Credit agreement originally dated October 12, 2023, previously amended July 8, 2024 and August 11, 2025

The filing

CompanyLigand Pharmaceuticals (LGND)
Form8-K, current report
Filed with the SECSep 16, 2025, 5:19 PM ET
Accession number0001193125-25-205147

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 16, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.